New drug cocktails tested for Tough-to-Treat blood cancer
NCT ID NCT04126200
Summary
This study is testing a targeted cancer drug called belantamab mafodotin, both by itself and in combination with several other anti-cancer drugs. It aims to find safe and effective treatment options for adults with multiple myeloma that has returned or stopped responding to prior therapies. The trial uses a flexible 'platform' design to efficiently test multiple drug combinations at once.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Atlanta, Georgia, 30322, United States
-
GSK Investigational Site
Indianapolis, Indiana, 46202, United States
-
GSK Investigational Site
Boston, Massachusetts, 02215, United States
-
GSK Investigational Site
Grand Rapids, Michigan, 49546, United States
-
GSK Investigational Site
Madison, Wisconsin, 53792, United States
-
GSK Investigational Site
Fitzroy, Victoria, 3065, Australia
-
GSK Investigational Site
Melbourne, Victoria, 3000, Australia
-
GSK Investigational Site
Porto Alegre, 90110-270, Brazil
-
GSK Investigational Site
Salvador, 41253-190, Brazil
-
GSK Investigational Site
São Paulo, 04537-080, Brazil
-
GSK Investigational Site
Vancouver, British Columbia, V5Z1M9, Canada
-
GSK Investigational Site
Halifax, Nova Scotia, B3H 1V7, Canada
-
GSK Investigational Site
Toronto, Ontario, M5G 2M9, Canada
-
GSK Investigational Site
Lille, 59037, France
-
GSK Investigational Site
Villejuif, 94805, France
-
GSK Investigational Site
Frankfurt, 60590, Germany
-
GSK Investigational Site
Hamburg, 20246, Germany
-
GSK Investigational Site
Kiel, 24105, Germany
-
GSK Investigational Site
Leipzig, 04103, Germany
-
GSK Investigational Site
Athens, 11528, Greece
-
GSK Investigational Site
Mexico City, 01330, Mexico
-
GSK Investigational Site
Leeuwarden, 8934 AD, Netherlands
-
GSK Investigational Site
Utrecht, 3584 CX, Netherlands
-
GSK Investigational Site
Oslo, 0450, Norway
-
GSK Investigational Site
Gdansk, 80-214, Poland
-
GSK Investigational Site
Katowice, 40-519, Poland
-
GSK Investigational Site
Lodz, 93-513, Poland
-
GSK Investigational Site
Lublin, 20-081, Poland
-
GSK Investigational Site
Moscow, 125284, Russia
-
GSK Investigational Site
Incheon, 21565, South Korea
-
GSK Investigational Site
Seoul, 03080, South Korea
-
GSK Investigational Site
Seoul, 06351, South Korea
-
GSK Investigational Site
Seoul, 06591, South Korea
-
GSK Investigational Site
Ulsan, 44033, South Korea
-
GSK Investigational Site
Badalona, 08916, Spain
-
GSK Investigational Site
Madrid, 28027, Spain
-
GSK Investigational Site
Madrid, 28040, Spain
-
GSK Investigational Site
Madrid, 28041, Spain
-
GSK Investigational Site
PamplonaNavarra, 31008, Spain
-
GSK Investigational Site
Pozuelo de AlarcOn Madr, 28223, Spain
-
GSK Investigational Site
Falun, SE-791 82, Sweden
-
GSK Investigational Site
Stockholm, SE-141 86, Sweden
Conditions
Explore the condition pages connected to this study.